HUMA vs. LLY
Compare and contrast key facts about Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HUMA or LLY.
Correlation
The correlation between HUMA and LLY is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
HUMA vs. LLY - Performance Comparison
Key characteristics
HUMA:
0.13
LLY:
0.81
HUMA:
1.01
LLY:
1.29
HUMA:
1.13
LLY:
1.17
HUMA:
0.16
LLY:
1.05
HUMA:
0.37
LLY:
2.44
HUMA:
37.09%
LLY:
10.39%
HUMA:
104.83%
LLY:
31.10%
HUMA:
-88.29%
LLY:
-68.27%
HUMA:
-75.57%
LLY:
-8.36%
Fundamentals
HUMA:
$533.97M
LLY:
$789.88B
HUMA:
-$1.34
LLY:
$11.86
HUMA:
$0.00
LLY:
$31.51B
HUMA:
-$3.61M
LLY:
$25.63B
HUMA:
-$110.85M
LLY:
$9.48B
Returns By Period
In the year-to-date period, HUMA achieves a -17.82% return, which is significantly lower than LLY's 13.77% return.
HUMA
-17.82%
-11.32%
-47.53%
32.38%
N/A
N/A
LLY
13.77%
11.57%
-1.20%
20.17%
45.08%
31.25%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HUMA vs. LLY — Risk-Adjusted Performance Rank
HUMA
LLY
HUMA vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Humacyte, Inc. (HUMA) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HUMA vs. LLY - Dividend Comparison
HUMA has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.59%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HUMA Humacyte, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.59% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
HUMA vs. LLY - Drawdown Comparison
The maximum HUMA drawdown since its inception was -88.29%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for HUMA and LLY. For additional features, visit the drawdowns tool.
Volatility
HUMA vs. LLY - Volatility Comparison
Humacyte, Inc. (HUMA) has a higher volatility of 17.08% compared to Eli Lilly and Company (LLY) at 11.06%. This indicates that HUMA's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
HUMA vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Humacyte, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities